Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15120989 | 0.87 | POLB (0.46) | CYP4F2CYP4A11FAAHPOLBMAPT | |
| SCHEMBL15120997 | 0.83 | CYP4F2 (0.47) | CYP4F2CYP4A11FAAHALOX5POLB | |
| SCHEMBL13742933 | 0.80 | PPID (0.40) | CYP4F2CYP4A11POLBL3MBTL1 | |
| SCHEMBL800069 | 0.79 | CYP4F2 (0.51) | CYP4F2CYP4A11TDP1FAAHCYP4Z1 | |
| Ethyl 3-Phenylpropanoate SCHEMBL304816 | 0.78 | TDP1 (0.75) | CYP4F2CYP4A11TDP1CYP4Z1ALOX5 | |
| SCHEMBL28208702 | 0.77 | CYP4F2 (0.66) | CYP4F2CYP4A11TDP1CYP4Z1EPHX2 | |
| Ethyl 3-Phenylpropanoate SCHEMBL7440447 | 0.76 | TDP1 (0.72) | CYP4F2CYP4A11TDP1CYP4Z1ALOX5 | |
| SCHEMBL68902 | 0.76 | CYP4F2 (0.85) | CYP4F2CYP4A11TDP1CYP4Z1EPHX2 | |
| SCHEMBL2773061 | 0.75 | CYP4F2 (0.68) | CYP4F2CYP4A11TDP1CYP4Z1ALOX5 | |
| SCHEMBL2772418 | 0.75 | CYP4F2 (0.68) | CYP4F2CYP4A11TDP1CYP4Z1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | CYP4F2 1625/4885CYP4A11 1497/4885TDP1 2860/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | CYP4F2 1614/4885CYP4A11 1459/4885TDP1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.